Original articleAlimentary tractUse of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines
Section snippets
Study Cohort
The population for this study consisted of women enrolled in the Crohn’s and Colitis Foundation PIANO registry, an ongoing prospective multicenter registry initiated in 2007. This prospective registry approached women with an established diagnosis of IBD receiving care at 1 of 30 centers throughout the United States. Upon obtaining informed consent, women provided detailed information regarding their demographics and characteristics of their IBD, including current and past treatments.
Results
The study population included 179 women from the PIANO registry who completed the vaccination survey. The mothers’ mean age was 31.6 years and the mean disease duration at the time of pregnancy was 9.5 years (Table 1). Two-thirds (67%) had Crohn’s disease (n = 120). One third of women each were in their first (n = 67; 37%) or second pregnancy (n = 55; 31%), while 24 women (13.4%) were in their fourth or subsequent pregnancy. Most women had inactive (77%) or mild disease activity (18%) at the
Discussion
The impact of medications used for the management of maternal IBD on the health and development of infants historically has not been studied systematically. With data showing that in utero exposure to some biologics leads to persistence of drug concentrations for up to a year, there is a need for robust examination of this effect on infant immune response. By using data from a rigorously followed up prospective cohort of pregnant women with IBD, we show that the rates of adequate serologic
Acknowledgments
The authors acknowledge the valuable contributions of the participants and the research staff of the Crohn’s and Colitis Foundation Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes registry.
References (23)
- et al.
Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection
Gastroenterology
(2016) - et al.
Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease
J Crohns Colitis
(2010) - et al.
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-alpha agents: effects of combined therapy with immunosuppressants
J Crohns Colitis
(2013) - et al.
Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease
Clin Gastroenterol Hepatol
(2007) - et al.
Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum
J Immunol Methods
(2012) - et al.
Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease
Clin Gastroenterol Hepatol
(2013) - et al.
Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - a systematic review of randomized trials, observational studies and case reports
Vaccine
(2017) - et al.
The effect of disease activity on birth outcomes in a nationwide cohort of women with moderate to severe inflammatory bowel disease
Inflamm Bowel Dis
(2017) - et al.
Safety of TNF-alpha inhibitors during IBD pregnancy: a systematic review
BMC Med
(2013) - et al.
Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease
Am J Gastroenterol
(2010)
The effect of maternal peripartum anti-TNFalpha use on infant immune response
Dig Dis Sci
Cited by (90)
Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy
2023, American Journal of Obstetrics and GynecologyThe Effect of In Utero Exposure to Maternal Inflammatory Bowel Disease and Immunomodulators on Infant Immune System Development and Function
2023, Cellular and Molecular Gastroenterology and HepatologyQuestions on Immunization and Vaccination and Short Answers
2023, Cocuk Enfeksiyon Dergisi
Conflicts of interest These authors disclose the following: Ashwin Ananthakrishnan has served on scientific advisory boards for Abbvie, Takeda, and Merck; Dawn Beaulieu has served as a consultant for Abbvie; Russell Cohen has served on the speaker’s Bureau for Abbvie and Takeda, has served as a consultant/on the advisory board/on the scientific advisory board for Abbvie, Celgene, Entera Health, Hospira, Janssen (Johnson & Johnson), Pfizer, Sandoz Biopharmaceuticals, Takeda, and UCB Pharma, has been the principal investigator for clinical trials for Astra-Zeneca, Celgene, Gilead Sciences, Medimmune, Mesoblast Ltd, Osiris Therapeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, and UCB Pharma; Sunanda Kane has served as a consultant for Abbvie, Janssen, Samsung Bioepis, 11 Health, and Spherix Global Health, has received research funding from UCB, and has served on the GI Specialty Board for ABIM; and Uma Mahadevan has served as a consultant for Abbvie, Janssen, UCB, and Takeda. The remaining author discloses no conflicts.
Funding This work was supported by the Crohn’s and Colitis Foundation.
- a
Authors share co-first authorship.